Harshal Khanwalkar

Retinoid receptor subtype-selective modulators through synthetic modifications of RARγ agonists

Susana Álvarez, Rosana Álvarez, Harshal Khanwalkar et al. · Bioorganic & Medicinal Chemistry · 2009 · 56 citations · Full text

Molecular Pharmacology, Synthetic Modifications, G Protein-coupled Receptor +5

Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008

Angela Nebbioso, Raquel Pereira, Harshal Khanwalkar et al. · Molecular Cancer Therapeutics · 2011 · 53 citations · Full text

Histone Modifications, Novel Epigenetic Modifier, Epigenetic Change +20

Modulating Retinoid X Receptor with a Series of (<i>E</i>)-3-[4-Hydroxy-3-(3-alkoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)phenyl]acrylic Acids and Their 4-Alkoxy Isomers

Efrén Pérez‐Santín, Pierre Germain, Fabien Quillard et al. · Journal of Medicinal Chemistry · 2009 · 46 citations

Potentiation of in vitro and in vivoantitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells

Maggie J. Rathos, Harshal Khanwalkar, Kavita Joshi et al. · BMC Cancer · 2013 · 40 citations · Full text

Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers

Maggie J. Rathos, Kavita Joshi, Harshal Khanwalkar et al. · Journal of Translational Medicine · 2012 · 40 citations · Full text